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Prostate‑specific Antigen as a Risk Factor for Skeletal
Metastasis in  Native Ethnic African Men with
Prostate Cancer: A Case‑control Study
Ayman M. Qureshi, Khalid Makhdomi, William Stones1
Department of Radiology, Aga Khan University, Nairobi, 1Department of Obstetrics and Gynaecology, Aga Khan University,
Nairobi, Kenya

Abstract
Prostate cancer is the most common noncutaneous cancer in males. Men of African origin are at a significantly higher risk as
reflected in the higher incidence and mortality rates in this racial group. Metastases incidence increases parallel to serum levels
of prostate‑specific antigen (PSA), contributing significantly to morbidity and mortality. Staging of the disease involves bone
scans, which are sensitive in detecting skeletal metastases. Suggestions that these scans may be omitted in some situations in
patients with low prostate specific antigen levels have drawn attention to the matter. In this case‑control study, using radiology and
pathology records, a registry of prostate cancer patients recorded as being of dark‑skinned ethnicity was obtained. Images were
presented to image reviewers blinded to the PSA level, to determine the presence of skeletal metastases. The risk factor for the
outcome of interest (skeletal metastases) was PSA level above 20 ng/mL. The reliability of image reporting was also assessed.
Of the 122 patients, skeletal metastases were present in 50 (41%) while these were absent in 72 (59%). The prevalence of
metastases among the high PSA group was 55.9% [95% confidence interval (CI) 44.1–67.7%] and among the normal/low PSA
group was 22.2% (95% CI 11.1–33.3%). The odds ratio (OR) for skeletal metastases in the exposed (high PSA) group was
4.4 (95% CI, 2.01–9.78.) Intraobserver agreement on image interpretation was 88.5% with a Kappa statistic of 0.76. A relatively
higher prevalence of skeletal metastasis is seen in regional dark‑skinned African males with prostate cancer at both low and high
prostate specific antigen levels. Bone scanning in this population should therefore, be considered even at PSA levels below 20 ng/mL.
Keywords: Bone scan, native ethnic African, prostate cancer, prostate‑specific antigen, skeletal metastases

Introduction
Carcinoma of the prostate is the most common
noncutaneous cancer in males, and the second most
common cause of cancer deaths in males.[1] Its incidence
rises significantly after the age of 50 years, and this
cancer is diagnosed in one in six men during their
lifetime. Multiple etiological factors are implicated in
the development of prostate cancer. Increasing age, a
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family history of disease, diet, and genetic factors have
all been linked.
Among the most striking factors related to the
development of prostate cancer, is race. Significantly,
higher rates of prostate cancer are seen in native ethnic
African males compared to Caucasian, Hispanic, and
Asian males. Age‑adjusted incidence rates (between
2002 and 2006) were 231.9 per 100,000 African Americans
versus 146.3 per 100,000 in Caucasians.[1] This made the
incidence among the American native ethnic African men
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1.6 times higher than White men. In addition, the death
rate among African Americans was 2.4 times higher than
Caucasians in the same time period (53.6 versus 26.3 per
100,000.) The differences in the incidence and mortality
are greater still, when comparing the rates in African
Americans to those among Hispanics, American Indians,
and Asians suggesting that African Americans are not
just at a higher risk of development of prostate cancer
but also appear to develop more aggressive disease.
Prostate cancer is the most common cancer in Africa
and sub‑Saharan Africa. In Eastern Africa, age‑adjusted
incidence rates for prostate cancer are the second highest
in this region after Kaposi sarcoma and esophageal
carcinoma. The disease burden in Africa appears to be
significant.[2]
Prostate‑specific antigen (PSA) is produced in
the prostatic epithelium but also by tumor cells.
A combination of increased cell burden and distorted
glandular architecture allowing the escape of prostate
specific antigen into systemic circulation is responsible
for the increased levels of prostate specific antigen in
prostate cancer.
The skeletal system is one of the most common sites
of metastasis, found in approximately 85% of patients
dying from prostate cancer. These metastases are
predominantly osteoblastic.
The bone scan (bone scintigraphy) is the most commonly
performed procedure for whole‑body screening and
assessment of skeletal metastasis [Figure 1]. As a baseline
investigation, it stages disease, demonstrates the extent
of the disease where metastases exist, and provides a
benchmark for follow‑up scans when assessing response
to treatment. The technique provides complementary
information to the anatomical information provided by
radiography, by demonstrating the metabolic changes
induced by bone pathology. Due to the osteoblastic
nature of prostate cancer metastases, metastatic
deposits manifest as areas of increased tracer uptake. In
extensive metastatic disease burden, diffuse uptake is
seen throughout the axial skeleton giving a “superscan”
appearance. Although the technique is relatively less
specific, it has substantially higher sensitivity compared
to radiography. Accurate disease staging can lead
to more appropriate decision‑making and advice to
patients. Management differs significantly in patients
with metastatic disease where the goal of therapy is
palliative, symptom control, and disease suppression,
versus eradication of the disease.
Performing bone scans in patients with PSA levels below
20 ng/mL remains a gray area in clinical practice. The
American Urology Association guidelines in its best

Figure 1: Bone scan images depicting normal uptake (left),
metastatic disease (middle), and a superscan (right)

practice statement of 2013 states that bone scans should
be considered at PSA levels below 10 ng/mL if the
tumor’s Gleason score is 8 or more or there is locally
advanced disease (≥T3).[3] By contrast, guidelines by the
European Association of Urology state that in locally
advanced disease or poorly differentiated tumors,
bone scans should be performed regardless of the PSA
value.[4] The Japanese Urological Association suggests
that bone scans may be eliminated when PSA levels are
less than 10 ng/mL in patients with well‑ differentiated
to moderately differentiated cancers.[5] A systematic
review examined the findings from 48 research
reports, 23 of which correlated baseline bone scan
findings as well as PSA levels. Out of 8,644 patients,
16.8% had metastases. Detection rates were 2.3%,
5.3%, and 16.2% in patients with PSA levels less than
10 ng/mL, 10.1–19.9 ng/mL, and 20 to 49.9 ng/mL,
respectively.[6] This meta‑analysis may be taken as a
global overview. However, men in the east African
region may be considered at a higher risk of developing
skeletal metastases on the basis of ethnicity or other
factors, based on the observation of a higher incidence
of and more aggressive prostate cancer in other dark
skinned populations worldwide. The present study was
undertaken so as to generate data on prostate cancer
metastasis to inform local and regional clinical practices.
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Materials and Methods
Based on a hypothesis that metastasis is more common
than the global estimate in our population, a sample size
calculation determined that a sample size of 120 (40 cases
and 80 controls) were required to detect an odds
ratio (OR) difference of 4 between patients with mildly
elevated PSA (<20 ng/mL) and high PSA (≥20 ng/mL),
at 91% power. This was derived from the pilot study data
entered into a power and sample size calculator (http://
biostat.mc.vanderbilt.edu/PowerSampleSize. Approx.
date of last access: 2012 December 20) where it was shown
that to detect a low OR at a high power, a moderate
number of cases were required [see Appendix 1.] Patients
with histologically confirmed prostate cancer who had a
bone scan between August 2011 and January 2013 at the
Aga Khan University Hospital, Nairobi, Nairobi County,
Kenya were consecutively collected for this retrospective
case‑control study, which was approved by the Research
Ethics Committee (Ref No: 2012/REC‑08(V2). Cases were
defined as patients with histologically proven prostate
cancer with skeletal metastases. Controls were defined
as patients with histologically proven prostate cancer
without skeletal metastases. The risk factor for outcome
of interest (skeletal metastases determined by bone scan)
was a PSA level greater than or equal to 20 ng/mL.
Inclusion criteria included native ethnic African patients
with histologically confirmed prostate cancer and a
serum PSA test within 3 months of the bone scan who
underwent bone scan for disease staging. Cases with
bone metastases due to malignancy other than prostate
cancer, posttherapy follow‑up bone scans, equivocal
cases without complementary images, and bone scans
reported by a radiologist other than the nuclear physician
were excluded from the study.
An initial listing of potentially eligible cases was acquired
from the departmental patient register. The indication
for the scan was confirmed from the radiology request
form. In the few instances where this information was
not provided, confirmation of the scan indication was
made from the patient’s file. Following the collection of
these data, the listing of cases was cross‑referenced with
the pathology department records to obtain   details of
histopathology where it was performed at the hospital.
Pathology reports from other hospitals were included
where available. Data collection began with the most
recently performed bone scans to assess prostate cancer
skeletal metastases, and proceeded retrospectively. The
sampling of patients was stratified into two groups:
those with mildly elevated or normal PSA (less than
20 ng/mL,) and those with highly elevated PSA (greater
than 20 ng/mL). The total number of patients acquired
was only slightly greater than the desired sample size;
therefore, sampling was nonrandom, and all eligible
cases were included in the analysis. PSA levels were
28

routinely collected from the patients prior to the bone
scan. The patients’ ethnicities were confirmed from the
patient registration section of the respective patient files
where this information is routinely recorded according
to hospital administrative procedures.
Data including patient identifiers were collected by
one investigator. Details including the patient’s name,
hospital number, and PSA level were entered into
a primary data collection table and each record was
coded, providing anonymity of the patient dataset and
achieving a blinding of subjects to the image reviewers.
Coded images were presented to the image reviewers
who entered the data into a separate data collection
table.
Technetium‑99 methylene diphosphonate (99mTc‑MDP)
whole‑body bone scans were performed on a dual
head gamma camera (Millennium MG, GE Medical
Systems, Milwaukee, WI, United States) 3–4 h following
intravenous (IV) injection of 99mTc‑MDP.
Image acquisition time for a whole‑body scan was
typically 20 min (camera speed of 11 cm/s); however,
these varied depending on the amount of activity
injected. Lower injected activities require a longer scan
time. A matrix of 1024 × 256 was used with a  low‑energy
high‑resolution collimator (GE Medical Systems,
Milwaukee, WI, United States). If necessary, spot views
of an area of interest were acquired. Five hundred
thousand counts were obtained of this site.
Images were analyzed by a nuclear physician (expert
reviewer) with over 15 years of experience in nuclear
medicine, and a registrar with cumulative total of
5 months training in nuclear medicine. The coded images
were uploaded onto the hospital picture archiving and
communication system (PACS) to a folder specific for the
purposes of the study. Through this system, images were
presented to the image reviewers using  Agfa® PACS
and  image viewing software (Mortsel, Belgium) on a
high‑resolution viewing monitor. The image reviewers
were blinded to the results of the PSA. In cases with
metastatic disease, sites of skeletal metastases were
listed by the nuclear physician. Results of the nuclear
physician’s repeat report were compared with the
original so as to determine intraobserver variability, and
comparison between the registrar’s report with the nuclear
physicians repeat report to test interobserver variability.
For comparison with PSA levels, the analysis was based
on the expert reviewer’s repeat report. In equivocal cases,
the image reviewers were provided with complementary
images in the same coded manner.
PSA levels in patients with and without skeletal
metastases and summary statistics for the distribution
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of PSA levels were calculated. Potential statistical
associations between PSA and skeletal metastases were
estimated using Chi‑square statistics. OR of skeletal
metastases between low and high PSA groups were
calculated. To determine the prevalence of skeletal
metastases in patients with PSA below 20 ng/mL a
two‑sample test for proportions was applied using the
global estimate of 3.5% for comparison.[6] Assessment
of intraobserver and interobserver agreement for
bone scans was quantified using Cohen’s kappa and
percentage of agreement.

Results
Within the 122 patient data sets included, 50 (41%)
were found to have skeletal metastases while 72 (59%)
had no skeletal metastases detectable on bone scan.
Sixty‑eight of the 122 PSA values (55.7%) were greater
than or equal to 20 ng/mL while 54 patients (44.3%)
were considered “unexposed” on the basis of PSA level
of below 20 ng/mL.
Among patients with and without skeletal metastases,
the PSA levels are summarized in Table 1 and Figure 2.
To illustrate the actual range of PSA values in the
sample population, the mean PSA in the “unexposed”
group (PSA less than 20 ng/mL) was 10.2 ± 5.0 ng/mL
(1–19.9 ng/mL) and the median PSA was 10 ng/mL. Within
the “exposed” group (PSA greater than 20 ng/mL), the
mean PSA was 441.4 ± 86.0 ng/mL (20–7000 ng/mL).
The median PSA value was 86 ng/mL.
Table 1: Summary statistics for distribution of PSA
in patients with and without skeletal metastases
No
Yes

Mean

Median

SD†

Min

Max

68.4
512.8

15.2
100

226.4
1101.5

1
1.02

1,800
7,000

†

SD: Standard deviation

In the present study, the OR for skeletal metastasis
was 4.4 [95% confidence interval (CI), 2.0–9.8] in the
exposed (high PSA) group. The prevalence of metastases
among this high PSA group was 55.9% (44.1–67.7%)
and 22.2% (11.1–33.3%) among the normal or low PSA
group. A two‑sample test of proportions was used to
compare these proportions with global estimates of
42.6% and 3.5%, respectively, for the high PSA group
and the normal or low PSA group. The prevalence
of metastases among the high PSA group differed
by 13.3% (95% CI, 1.2–25.4%; P = 0.031) compared
to the global estimate. Among the low PSA group,
the prevalence differed by 18.7% (95% CI, 7.6–29.8%;
P = 0.001) from the estimated global average.
The sites of skeletal metastases varied, with the spine,
pelvis, and rib cage representing the most common
sites. These data are summarized in a bar graph format
[Figure 3].
Intraobserver and interobserver agreement of reporting
was performed using kappa statistics. There was an
88.5% agreement between the expert reviewer’s original
and repeat reports, giving a kappa value of 0.76,
indicating substantial agreement. Agreement between
the registrar and expert reviewer reports was 85.3%,
with a kappa value of 0.70, also indicating substantial
agreement.

Discussion
The increasing role of PSA as a screening tool for
prostatic disease has led to an increase in the diagnosis
of prostate cancer, with more cancers being detected at
an earlier stage. The need for staging of prostate cancer
is important for optimal management, which includes
radical prostatectomy for organ‑confined disease and
androgen deprivation therapy for metastatic disease.
Forty‑one percent of the patients in our study had skeletal
metastases as assessed on bone scans using methods for
which good reliability was demonstrated. This is over

Figure 2: Box plot displaying summary statistics for PSA in cases
with and without metastasis

Figure 3: Summary of frequency and percentage involvement of
various sites of skeletal metastases
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twice the proportion seen in the systematic review by
Abuzallouf et al. where 1,453 out of 8,644 patients (16.8%)
had positive bone scans. The inclusion of solely native
ethnic African patients  in the present study may be a
possible explanation for the large difference. Data from
other dark skinned populations have shown higher
prostate cancer incidence and mortality within men
of  African descent that is consistent with a truly greater
prevalence of the disease in this group.[1] Fifty‑six percent
of the patients in our study had a PSA level greater
than or equal to 20 ng/mL while 44.3% had a PSA level
below 20 ng/mL. A considerable difference is seen
between the present findings, compared to those from
the meta‑analysis where 27.8% of the patients had a PSA
level of greater than or equal to 20 ng/mL, and 72.2%
had a PSA level of less than 20 ng/mL. This reflects the
case mix and inclusion criteria in reported studies, with
many reporting the results of evaluation for skeletal
metastases at PSA levels less than 20 ng/mL.
The mean PSA level was five times higher in patients
with skeletal metastases than those without skeletal
metastases in the current study––a finding that is
expected, considering that the incidence of skeletal
metastases increases with an increase in the PSA level.
Of the patients without metastases, most were in the
low PSA group, as indicated by a median PSA value of
15.2 ng/mL. Within the high PSA group, the median PSA
was 86 ng/mL. An important observation with clinical
implications in our sample is the wide distribution of
PSA levels among patients with skeletal metastases,
including those below 20 ng/mL.
We documented a higher prevalence of skeletal
metastasis in the regional native ethnic African
population relative to the typical global pattern,
especially those with a low PSA level. Indeed, the
prevalence of metastasis was considerably greater
than that seen in East Asian studies and among Arab
populations, which is consistent with the existing
data that indicate that these ethnic groups have a
lower incidence and mortality from prostate cancer.
[7‑10]
Five studies from the systematic review reported
a prevalence of skeletal metastases above 10% at PSA
levels below 20 ng/mL, with reported ranges from 11.7%
to 15.9%.[11‑15] The prevalence of skeletal metastasis in
these studies is still noted to be somewhat lower than
the current study population. A possible reason for this
is the ethnic differences of patients in these studies from
the current study, which exclusively evaluated native
ethnic African males. Our findings are consistent with
the conclusion that skeletal metastases from prostate
cancer occur earlier in men of African descent, and
that the biological aggressiveness of prostate cancer
within this population may be higher than that seen
within non‑native ethnic African male populations.
30

These findings are parallel to reports showing that the
incidence of and mortality rates from prostate cancer
within the east African region are high.[2]
In the current study, the spine, pelvis, and ribs were
the most common sites of skeletal metastasis. The
probable reasons for this include the fact that the
above sites are abundant in cancellous bone, which
has a rich blood supply. During the passage of blood
through tight sinusoids in this bone structure, there is
a slowing of blood flow allowing deposition of tumor
cells. In addition, tethering proteins such as vascular
cell adhesion molecule 1 (VCAM‑1) are moderately
expressed and interact with neoplastic cells, anchoring
them to the bone.[16] This pathophysiological mechanism
also explains why the upper and lower limbs are
affected (32% and 20%, respectively); however, it does
not explain why this is less than the previously described
regions. A possible explanation is the conversion of red
marrow, and subsequent reduction in blood supply to
the bone marrow compared to the previously described
areas where residual red marrow exists in relative
abundance.

Conclusions
The results from the present study suggest that prostate
cancer within the East African native male population
demonstrates aggressive biological behavior, similar to
that seen in African American populations. Based on
our findings, we consider bone scans should be ordered
for prostate cancer patients with PSA levels less than
20 ng/mL, and in our setting those with levels less than
10 ng/mL should also be investigated. The need for
scanning is obviously greater if patients have coexisting
risk factors for skeletal metastasis such as high Gleason’s
scores or extra prostatic disease extension, and there is
therefore, a role for further research in this field locally.
Establishing the infrastructure and logistics required
to run a nuclear medicine facility are challenging in
low‑resource settings. Aspects of this are training and
retention of specialist personnel, consistent procurement
of radionuclide generators and radiopharmaceuticals,
the maintenance of infrastructure that meets radiation
safety standards, and the ability to sustain the service
through realistic cost recovery and adequate volume
of cases referred for investigation. We consider that
the appropriate way forward is to concentrate such
services within larger tertiary referral centers alongside
arrangements to enable a wide access through effective
referral linkages that deal with practical arrangements
such as travel and accommodation. In sub‑Saharan Africa,
resourcing such developments may be best undertaken
via public–private collaboration on cancer services using
mechanisms such as service level agreements involving
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partners at the regional as well as national levels, as for
many countries undertaking these developments would
be unrealistic. Furthermore, some countries are currently
developing or implementing national cancer strategies
so that related regional collaboration would be timely.
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Appendix 1
No. of cases
50

40

30

20

18

15

OR† desired
to be detected

Power to detect
the desired OR

2
3
4
2
3
4
3
4
5
4
5
6
7
8
6
7
8
9
10
8
9
10
11
12

0.434
0.841
0.967
0.347
0.740
0.916
0.592
0.805
0.910
0.590
0.728
0.819
0.879
0.917
0.765
0.832
0.878
0.910
0.933
0.788
0.830
0.863
0.888
0.907

†

OR: Odds ratio
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